Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs)
Forecasted Federal grant Posted
- Opportunity number
- RFA-MH-27-150
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications expected due
- Award size
- Not on record
Opportunity facts
- Expected posting
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- For Profit Organizations
- Tribal Organizations (Not Federally Recognized)
- County Governments
- Small Businesses
- City/Township Governments
- State Governments
- Independent School Districts
- Higher Education Inst. (Public)
- Public or Indian Housing Auth.
- Special District Governments
- Non-501(c)(3) Nonprofits
- Other
- 501(c)(3) Nonprofits
- Tribal Governments (Federally Recognized)
- Higher Education Inst. (Private)
- Points of contact
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institute of Mental Health is forecasting a Notice of Funding Opportunity to support development of a research network studying rapid-acting psychotropic interventional drugs (RAPIDs)—including ketamine, esketamine, psilocybin, and other emerging treatments for serious mental illnesses—with application due date in October 2026 or later. The opportunity funds cooperative agreements under CFDA 93.242 (Mental Health Research Grants).
Eligible applicants include for-profit organizations, tribal organizations (federally and non-federally recognized), county and city governments, state governments, school districts, public and private higher education institutions, housing authorities, special district governments, nonprofits (501(c)(3) and non-501(c)(3)), eligible federal agencies, faith-based or community-based organizations, regional organizations, and U.S. territories or possessions.
The primary objective is generating actionable evidence on clinical effectiveness, safety, and implementation of RAPIDs to identify how these interventions can be delivered safely, effectively, and sustainably across diverse patients, providers, and health care settings. The resulting evidence will inform how RAPIDs can be integrated into clinical care and may shape future health care delivery approaches.
NIMH anticipates funding a research network addressing critical gaps: preliminary studies show RAPIDs produce clinically meaningful improvements in mental health outcomes in some cases after a single dose, but questions remain regarding durability of benefit, safety profiles, and implementation in routine clinical practice.
Project periods do not exceed five years. All applications undergo scientific peer review by an appropriate panel and review by the National Advisory Mental Health Council. Funding decisions consider technical merit, program relevance, program balance, and fund availability.
Forecast synopsis
The National Institute of Mental Health (NIMH) intends to publish a Notice of Funding Opportunity (NOFO) to support the development of a research network to study rapid-acting psychotropic interventional drugs (RAPIDs), such as ketamine, esketamine, psilocybin, and other emerging treatments for serious mental illnesses.
Preliminary studies suggest that RAPIDs can produce clinically meaningful improvements in mental health outcomes, in some cases following a single dose. However, important questions remain regarding their effectiveness, safety, durability of benefit, and implementation in routine clinical practice. As these interventions move toward broader use, rigorous real-world evidence is needed to identify how RAPIDs can be delivered safely, effectively, and sustainably across diverse patients, providers, and health care settings.
The primary goal of this NOFO is to generate actionable evidence on the clinical effectiveness, safety, and implementation of RAPIDs. The resulting evidence from this study will help determine how RAPIDs can be safely and effectively integrated into clinical care and may inform future approaches to health care delivery.
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity